Share Price and Basic Stock Data
Last Updated: October 28, 2025, 6:53 pm
| PEG Ratio | 2.96 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Poly Medicure Ltd operates in the medical equipment and accessories sector, delivering consistent revenue growth over the years. For the fiscal year ending March 2025, the company reported sales of ₹1,669 Cr, a significant increase from ₹1,375 Cr in the previous fiscal year. This represents a compounded annual growth rate (CAGR) of approximately 25.5% over the last two years. Quarterly sales data indicates a steady upward trajectory, with revenues rising from ₹249 Cr in June 2022 to ₹378 Cr by March 2024. The trend continued, with sales reaching ₹441 Cr in March 2025. The operating profit margin (OPM) has been robust, standing at 27% for the latest fiscal year, reflecting effective cost management and operational efficiency. Overall, Poly Medicure has demonstrated a strong capacity to capitalize on the growing demand for medical devices, driven by an increasing focus on healthcare infrastructure in India.
Profitability and Efficiency Metrics
Poly Medicure’s profitability metrics illustrate its efficient management and operational strategies. The company recorded a net profit of ₹339 Cr for the fiscal year ending March 2025, up from ₹258 Cr in the prior year, indicating a growth rate of around 31.3%. The net profit margin stood at 19.96%, which is above the typical industry average, showcasing effective cost control. The return on equity (ROE) was reported at 15.8%, while the return on capital employed (ROCE) was 20.1%, both of which are commendable compared to sector benchmarks. Furthermore, the interest coverage ratio (ICR) of 45.18x highlights the company’s strong ability to meet its interest obligations, indicating financial stability. However, the cash conversion cycle (CCC) of 239 days suggests potential inefficiencies in inventory management and receivables collection, which could impact liquidity if not addressed.
Balance Sheet Strength and Financial Ratios
Poly Medicure’s balance sheet reflects a robust financial position with total assets amounting to ₹3,192 Cr as of March 2025. The company reported reserves of ₹2,715 Cr, indicating strong retained earnings that can be utilized for future growth initiatives. The total borrowings stood at ₹180 Cr, which translates to a low debt-to-equity ratio of 0.06, signifying a conservative capital structure and minimal financial risk. The current ratio of 5.18x demonstrates superior liquidity, far exceeding the typical industry range, which provides a buffer against short-term financial obligations. Additionally, the price-to-book value (P/BV) ratio of 8.21x suggests that the stock may be trading at a premium, reflecting investor confidence in the company’s future prospects. However, the high P/BV ratio also raises concerns about valuation, particularly if growth expectations are not met.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Poly Medicure reveals a strong confidence from promoters and institutional investors. As of March 2025, promoters held 62.44% of the company’s shares, indicating significant insider ownership that aligns their interests with those of other shareholders. Foreign institutional investors (FIIs) accounted for 11.41%, while domestic institutional investors (DIIs) held 11.72%. The public shareholding stood at 14.43%, with the total number of shareholders increasing to 71,142, reflecting growing retail interest and confidence in the company’s prospects. However, the slight decline in FII participation from previous periods may raise questions about foreign investor sentiment. The overall distribution suggests a stable investor base, contributing to the company’s resilience and long-term growth strategy.
Outlook, Risks, and Final Insight
Looking ahead, Poly Medicure is well-positioned to capitalize on the expanding healthcare sector in India, driven by increasing healthcare expenditures and a growing population. However, potential risks include fluctuations in raw material prices and regulatory changes that could impact operational costs. Additionally, the company’s relatively high cash conversion cycle could pose liquidity challenges if not managed effectively. If Poly Medicure can enhance its inventory management and continue to innovate within its product offerings, it stands to benefit from the rising demand for medical devices in both domestic and international markets. Conversely, failure to address these operational inefficiencies may hinder its growth potential. Overall, Poly Medicure’s strong fundamentals and market position provide a solid foundation for future performance, contingent on effective management of its identified risks.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Poly Medicure Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Constronics Infra Ltd | 80.8 Cr. | 64.5 | 158/46.0 | 19.2 | 30.9 | 0.00 % | 19.7 % | 15.8 % | 10.0 |
| Centenial Surgical Suture Ltd | 39.0 Cr. | 107 | 189/82.2 | 84.3 | 0.00 % | 3.94 % | 4.64 % | 10.0 | |
| Adeshwar Meditex Ltd | 27.6 Cr. | 19.1 | 26.5/15.0 | 13.9 | 25.6 | 0.00 % | 8.27 % | 5.51 % | 10.0 |
| Poly Medicure Ltd | 19,316 Cr. | 1,906 | 3,358/1,821 | 54.0 | 273 | 0.18 % | 20.1 % | 15.8 % | 5.00 |
| Mohini Health & Hygiene Ltd | 83.9 Cr. | 46.0 | 86.9/45.2 | 8.12 | 57.8 | 0.00 % | 14.1 % | 10.0 % | 10.0 |
| Industry Average | 19,316.00 Cr | 428.52 | 23.81 | 94.32 | 0.04% | 13.22% | 10.35% | 9.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 249 | 275 | 285 | 307 | 321 | 337 | 340 | 378 | 385 | 420 | 424 | 441 | 403 |
| Expenses | 202 | 210 | 214 | 224 | 234 | 253 | 249 | 282 | 281 | 305 | 310 | 321 | 297 |
| Operating Profit | 46 | 65 | 71 | 83 | 87 | 84 | 90 | 96 | 104 | 115 | 115 | 119 | 106 |
| OPM % | 19% | 24% | 25% | 27% | 27% | 25% | 27% | 26% | 27% | 27% | 27% | 27% | 26% |
| Other Income | 5 | 9 | 15 | 9 | 14 | 15 | 17 | 15 | 17 | 27 | 24 | 27 | 43 |
| Interest | 1 | 0 | 5 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
| Depreciation | 14 | 14 | 14 | 15 | 16 | 16 | 16 | 16 | 20 | 21 | 22 | 21 | 23 |
| Profit before tax | 36 | 59 | 67 | 75 | 83 | 81 | 88 | 92 | 98 | 118 | 113 | 123 | 123 |
| Tax % | 26% | 27% | 25% | 22% | 24% | 23% | 26% | 26% | 25% | 26% | 25% | 25% | 24% |
| Net Profit | 27 | 44 | 50 | 59 | 63 | 62 | 65 | 68 | 74 | 87 | 85 | 92 | 93 |
| EPS in Rs | 2.81 | 4.54 | 5.21 | 6.13 | 6.54 | 6.48 | 6.78 | 7.12 | 7.71 | 8.63 | 8.41 | 9.06 | 9.19 |
Last Updated: August 20, 2025, 5:25 am
Below is a detailed analysis of the quarterly data for Poly Medicure Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 403.00 Cr.. The value appears to be declining and may need further review. It has decreased from 441.00 Cr. (Mar 2025) to 403.00 Cr., marking a decrease of 38.00 Cr..
- For Expenses, as of Jun 2025, the value is 297.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 321.00 Cr. (Mar 2025) to 297.00 Cr., marking a decrease of 24.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 106.00 Cr.. The value appears to be declining and may need further review. It has decreased from 119.00 Cr. (Mar 2025) to 106.00 Cr., marking a decrease of 13.00 Cr..
- For OPM %, as of Jun 2025, the value is 26.00%. The value appears to be declining and may need further review. It has decreased from 27.00% (Mar 2025) to 26.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is 43.00 Cr.. The value appears strong and on an upward trend. It has increased from 27.00 Cr. (Mar 2025) to 43.00 Cr., marking an increase of 16.00 Cr..
- For Interest, as of Jun 2025, the value is 3.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 23.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 21.00 Cr. (Mar 2025) to 23.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 123.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 123.00 Cr..
- For Tax %, as of Jun 2025, the value is 24.00%. The value appears to be improving (decreasing) as expected. It has decreased from 25.00% (Mar 2025) to 24.00%, marking a decrease of 1.00%.
- For Net Profit, as of Jun 2025, the value is 93.00 Cr.. The value appears strong and on an upward trend. It has increased from 92.00 Cr. (Mar 2025) to 93.00 Cr., marking an increase of 1.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 9.19. The value appears strong and on an upward trend. It has increased from 9.06 (Mar 2025) to 9.19, marking an increase of 0.13.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:39 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 322 | 390 | 411 | 454 | 519 | 610 | 687 | 785 | 922 | 1,115 | 1,375 | 1,669 | 1,688 |
| Expenses | 246 | 304 | 323 | 361 | 397 | 479 | 520 | 569 | 707 | 847 | 1,014 | 1,214 | 1,233 |
| Operating Profit | 76 | 86 | 88 | 93 | 122 | 131 | 166 | 216 | 215 | 267 | 361 | 455 | 455 |
| OPM % | 24% | 22% | 21% | 21% | 23% | 22% | 24% | 28% | 23% | 24% | 26% | 27% | 27% |
| Other Income | 11 | 28 | 8 | 14 | 16 | 20 | 21 | 22 | 40 | 38 | 60 | 94 | 120 |
| Interest | 9 | 10 | 10 | 8 | 12 | 14 | 20 | 11 | 6 | 11 | 14 | 14 | 12 |
| Depreciation | 14 | 19 | 21 | 24 | 29 | 37 | 41 | 48 | 54 | 57 | 63 | 83 | 87 |
| Profit before tax | 63 | 85 | 65 | 75 | 97 | 100 | 126 | 180 | 195 | 237 | 344 | 453 | 477 |
| Tax % | 30% | 27% | 27% | 27% | 27% | 35% | 24% | 25% | 25% | 25% | 25% | 25% | |
| Net Profit | 45 | 62 | 48 | 55 | 71 | 65 | 96 | 136 | 147 | 179 | 258 | 339 | 358 |
| EPS in Rs | 5.11 | 7.07 | 5.47 | 6.25 | 8.00 | 7.41 | 10.86 | 14.17 | 15.28 | 18.69 | 26.91 | 33.41 | 35.29 |
| Dividend Payout % | 20% | 18% | 27% | 40% | 25% | 27% | 18% | 18% | 16% | 16% | 11% | 10% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 37.78% | -22.58% | 14.58% | 29.09% | -8.45% | 47.69% | 41.67% | 8.09% | 21.77% | 44.13% | 31.40% |
| Change in YoY Net Profit Growth (%) | 0.00% | -60.36% | 37.16% | 14.51% | -37.54% | 56.14% | -6.03% | -33.58% | 13.68% | 22.37% | -12.74% |
Poly Medicure Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 19% |
| 3 Years: | 22% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 29% |
| 3 Years: | 34% |
| TTM: | 33% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 35% |
| 3 Years: | 33% |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 16% |
| 3 Years: | 17% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 12:20 pm
Balance Sheet
Last Updated: September 10, 2025, 2:16 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 44 | 44 | 44 | 44 | 48 | 48 | 48 | 48 | 51 |
| Reserves | 124 | 174 | 207 | 227 | 294 | 337 | 391 | 918 | 1,040 | 1,194 | 1,422 | 2,715 |
| Borrowings | 67 | 79 | 82 | 101 | 133 | 161 | 207 | 137 | 127 | 149 | 174 | 180 |
| Other Liabilities | 73 | 89 | 76 | 85 | 94 | 112 | 126 | 121 | 163 | 187 | 215 | 246 |
| Total Liabilities | 286 | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,192 |
| Fixed Assets | 123 | 165 | 182 | 207 | 265 | 306 | 363 | 426 | 488 | 635 | 867 | 1,084 |
| CWIP | 20 | 10 | 14 | 20 | 18 | 19 | 25 | 21 | 43 | 78 | 76 | 101 |
| Investments | 3 | 4 | 4 | 3 | 17 | 8 | 25 | 354 | 346 | 132 | 167 | 1,077 |
| Other Assets | 140 | 185 | 187 | 227 | 264 | 321 | 354 | 422 | 499 | 732 | 748 | 930 |
| Total Assets | 286 | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,192 |
Below is a detailed analysis of the balance sheet data for Poly Medicure Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 51.00 Cr.. The value appears strong and on an upward trend. It has increased from 48.00 Cr. (Mar 2024) to 51.00 Cr., marking an increase of 3.00 Cr..
- For Reserves, as of Mar 2025, the value is 2,715.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,422.00 Cr. (Mar 2024) to 2,715.00 Cr., marking an increase of 1,293.00 Cr..
- For Borrowings, as of Mar 2025, the value is 180.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 174.00 Cr. (Mar 2024) to 180.00 Cr., marking an increase of 6.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 246.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 215.00 Cr. (Mar 2024) to 246.00 Cr., marking an increase of 31.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 3,192.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,859.00 Cr. (Mar 2024) to 3,192.00 Cr., marking an increase of 1,333.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 1,084.00 Cr.. The value appears strong and on an upward trend. It has increased from 867.00 Cr. (Mar 2024) to 1,084.00 Cr., marking an increase of 217.00 Cr..
- For CWIP, as of Mar 2025, the value is 101.00 Cr.. The value appears strong and on an upward trend. It has increased from 76.00 Cr. (Mar 2024) to 101.00 Cr., marking an increase of 25.00 Cr..
- For Investments, as of Mar 2025, the value is 1,077.00 Cr.. The value appears strong and on an upward trend. It has increased from 167.00 Cr. (Mar 2024) to 1,077.00 Cr., marking an increase of 910.00 Cr..
- For Other Assets, as of Mar 2025, the value is 930.00 Cr.. The value appears strong and on an upward trend. It has increased from 748.00 Cr. (Mar 2024) to 930.00 Cr., marking an increase of 182.00 Cr..
- For Total Assets, as of Mar 2025, the value is 3,192.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,859.00 Cr. (Mar 2024) to 3,192.00 Cr., marking an increase of 1,333.00 Cr..
Notably, the Reserves (2,715.00 Cr.) exceed the Borrowings (180.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 9.00 | 7.00 | 6.00 | -8.00 | -11.00 | -30.00 | -41.00 | 79.00 | 88.00 | 118.00 | 187.00 | 275.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 52 | 59 | 74 | 77 | 79 | 77 | 68 | 72 | 82 | 77 | 72 | 76 |
| Inventory Days | 142 | 148 | 114 | 194 | 161 | 186 | 241 | 217 | 218 | 237 | 205 | 233 |
| Days Payable | 101 | 101 | 76 | 131 | 96 | 123 | 142 | 111 | 115 | 105 | 89 | 71 |
| Cash Conversion Cycle | 94 | 106 | 111 | 140 | 144 | 139 | 166 | 179 | 185 | 209 | 188 | 239 |
| Working Capital Days | 20 | 25 | 35 | 55 | 71 | 56 | 44 | 74 | 81 | 69 | 54 | 74 |
| ROCE % | 33% | 30% | 26% | 24% | 26% | 22% | 25% | 22% | 17% | 18% | 24% | 20% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| UTI Flexi Cap Fund | 2,144,773 | 1.24 | 312.42 | 2,144,773 | 2025-04-22 16:11:32 | 0% |
| Quant Small Cap Fund | 1,043,752 | 0.97 | 152.04 | 1,043,752 | 2025-04-22 16:11:32 | 0% |
| UTI Unit Linked Insurance Plan (ULIP) - Fifteen Year Plan | 180,609 | 0.5 | 26.31 | 180,609 | 2025-04-22 07:46:55 | 0% |
| UTI Unit Linked Insurance Plan (ULIP) - Ten Year Plan | 180,609 | 0.5 | 26.31 | 180,609 | 2025-04-22 05:20:40 | 0% |
| WhiteOak Capital Flexi Cap Fund | 140,638 | 0.69 | 20.49 | 140,638 | 2025-04-22 15:56:54 | 0% |
| Bank of India Small Cap Fund | 96,500 | 1.54 | 14.06 | 96,500 | 2025-04-22 15:56:54 | 0% |
| UTI Healthcare Fund | 62,328 | 0.99 | 9.08 | 62,328 | 2025-04-22 15:56:54 | 0% |
| WhiteOak Capital Mid Cap Fund | 51,906 | 0.49 | 7.56 | 51,906 | 2025-04-22 15:56:54 | 0% |
| Bank of India ELSS Tax Saver | 49,768 | 0.66 | 7.25 | 49,768 | 2025-04-22 16:11:32 | 0% |
| Bank of India ELSS Tax Saver - Eco Plan | 49,768 | 0.66 | 7.25 | 49,768 | 2025-04-22 15:56:54 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 34.13 | 26.92 | 18.69 | 15.28 | 15.25 |
| Diluted EPS (Rs.) | 34.11 | 26.90 | 18.67 | 15.27 | 15.24 |
| Cash EPS (Rs.) | 41.06 | 33.31 | 24.44 | 20.65 | 18.78 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 272.95 | 153.18 | 129.41 | 113.40 | 100.71 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 272.95 | 153.18 | 129.41 | 113.40 | 100.71 |
| Revenue From Operations / Share (Rs.) | 164.80 | 143.35 | 116.24 | 96.25 | 82.03 |
| PBDIT / Share (Rs.) | 53.49 | 43.45 | 31.43 | 26.17 | 24.28 |
| PBIT / Share (Rs.) | 45.33 | 36.79 | 25.47 | 20.55 | 19.32 |
| PBT / Share (Rs.) | 44.15 | 35.61 | 24.55 | 20.10 | 18.43 |
| Net Profit / Share (Rs.) | 32.90 | 26.65 | 18.48 | 15.02 | 13.83 |
| NP After MI And SOA / Share (Rs.) | 33.41 | 26.91 | 18.69 | 15.28 | 14.17 |
| PBDIT Margin (%) | 32.45 | 30.30 | 27.04 | 27.19 | 29.59 |
| PBIT Margin (%) | 27.50 | 25.66 | 21.91 | 21.34 | 23.55 |
| PBT Margin (%) | 26.78 | 24.83 | 21.12 | 20.88 | 22.47 |
| Net Profit Margin (%) | 19.96 | 18.58 | 15.90 | 15.60 | 16.85 |
| NP After MI And SOA Margin (%) | 20.27 | 18.77 | 16.07 | 15.87 | 17.27 |
| Return on Networth / Equity (%) | 12.24 | 17.56 | 14.43 | 13.47 | 14.07 |
| Return on Capital Employeed (%) | 16.27 | 23.42 | 19.03 | 17.13 | 17.60 |
| Return On Assets (%) | 10.60 | 13.89 | 11.36 | 10.64 | 11.10 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.01 | 0.03 | 0.06 |
| Total Debt / Equity (X) | 0.06 | 0.11 | 0.11 | 0.11 | 0.10 |
| Asset Turnover Ratio (%) | 0.66 | 0.80 | 0.73 | 0.68 | 0.76 |
| Current Ratio (X) | 5.18 | 2.40 | 2.75 | 3.46 | 4.12 |
| Quick Ratio (X) | 4.41 | 1.77 | 2.04 | 2.71 | 3.38 |
| Inventory Turnover Ratio (X) | 2.26 | 2.16 | 2.25 | 2.39 | 2.22 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 11.14 | 13.37 | 16.36 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 8.93 | 10.14 | 11.95 | 0.00 |
| Earning Retention Ratio (%) | 0.00 | 88.86 | 86.63 | 83.64 | 0.00 |
| Cash Earning Retention Ratio (%) | 0.00 | 91.07 | 89.86 | 88.05 | 0.00 |
| Interest Coverage Ratio (X) | 45.18 | 36.90 | 34.12 | 58.99 | 27.35 |
| Interest Coverage Ratio (Post Tax) (X) | 28.79 | 23.63 | 21.07 | 34.86 | 16.57 |
| Enterprise Value (Cr.) | 22744.56 | 15271.32 | 9107.85 | 9208.87 | 7911.73 |
| EV / Net Operating Revenue (X) | 13.62 | 11.10 | 8.17 | 9.98 | 10.06 |
| EV / EBITDA (X) | 41.97 | 36.62 | 30.20 | 36.69 | 33.99 |
| MarketCap / Net Operating Revenue (X) | 13.61 | 11.08 | 8.20 | 9.86 | 9.97 |
| Retention Ratios (%) | 0.00 | 88.85 | 86.62 | 83.63 | 0.00 |
| Price / BV (X) | 8.21 | 10.37 | 7.36 | 8.37 | 8.12 |
| Price / Net Operating Revenue (X) | 13.61 | 11.08 | 8.20 | 9.86 | 9.97 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Poly Medicure Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 34.13. This value is within the healthy range. It has increased from 26.92 (Mar 24) to 34.13, marking an increase of 7.21.
- For Diluted EPS (Rs.), as of Mar 25, the value is 34.11. This value is within the healthy range. It has increased from 26.90 (Mar 24) to 34.11, marking an increase of 7.21.
- For Cash EPS (Rs.), as of Mar 25, the value is 41.06. This value is within the healthy range. It has increased from 33.31 (Mar 24) to 41.06, marking an increase of 7.75.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 272.95. It has increased from 153.18 (Mar 24) to 272.95, marking an increase of 119.77.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 272.95. It has increased from 153.18 (Mar 24) to 272.95, marking an increase of 119.77.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 164.80. It has increased from 143.35 (Mar 24) to 164.80, marking an increase of 21.45.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 53.49. This value is within the healthy range. It has increased from 43.45 (Mar 24) to 53.49, marking an increase of 10.04.
- For PBIT / Share (Rs.), as of Mar 25, the value is 45.33. This value is within the healthy range. It has increased from 36.79 (Mar 24) to 45.33, marking an increase of 8.54.
- For PBT / Share (Rs.), as of Mar 25, the value is 44.15. This value is within the healthy range. It has increased from 35.61 (Mar 24) to 44.15, marking an increase of 8.54.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 32.90. This value is within the healthy range. It has increased from 26.65 (Mar 24) to 32.90, marking an increase of 6.25.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 33.41. This value is within the healthy range. It has increased from 26.91 (Mar 24) to 33.41, marking an increase of 6.50.
- For PBDIT Margin (%), as of Mar 25, the value is 32.45. This value is within the healthy range. It has increased from 30.30 (Mar 24) to 32.45, marking an increase of 2.15.
- For PBIT Margin (%), as of Mar 25, the value is 27.50. This value exceeds the healthy maximum of 20. It has increased from 25.66 (Mar 24) to 27.50, marking an increase of 1.84.
- For PBT Margin (%), as of Mar 25, the value is 26.78. This value is within the healthy range. It has increased from 24.83 (Mar 24) to 26.78, marking an increase of 1.95.
- For Net Profit Margin (%), as of Mar 25, the value is 19.96. This value exceeds the healthy maximum of 10. It has increased from 18.58 (Mar 24) to 19.96, marking an increase of 1.38.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 20.27. This value exceeds the healthy maximum of 20. It has increased from 18.77 (Mar 24) to 20.27, marking an increase of 1.50.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.24. This value is below the healthy minimum of 15. It has decreased from 17.56 (Mar 24) to 12.24, marking a decrease of 5.32.
- For Return on Capital Employeed (%), as of Mar 25, the value is 16.27. This value is within the healthy range. It has decreased from 23.42 (Mar 24) to 16.27, marking a decrease of 7.15.
- For Return On Assets (%), as of Mar 25, the value is 10.60. This value is within the healthy range. It has decreased from 13.89 (Mar 24) to 10.60, marking a decrease of 3.29.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has decreased from 0.11 (Mar 24) to 0.06, marking a decrease of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.66. It has decreased from 0.80 (Mar 24) to 0.66, marking a decrease of 0.14.
- For Current Ratio (X), as of Mar 25, the value is 5.18. This value exceeds the healthy maximum of 3. It has increased from 2.40 (Mar 24) to 5.18, marking an increase of 2.78.
- For Quick Ratio (X), as of Mar 25, the value is 4.41. This value exceeds the healthy maximum of 2. It has increased from 1.77 (Mar 24) to 4.41, marking an increase of 2.64.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.26. This value is below the healthy minimum of 4. It has increased from 2.16 (Mar 24) to 2.26, marking an increase of 0.10.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 11.14 (Mar 24) to 0.00, marking a decrease of 11.14.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 8.93 (Mar 24) to 0.00, marking a decrease of 8.93.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 88.86 (Mar 24) to 0.00, marking a decrease of 88.86.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 91.07 (Mar 24) to 0.00, marking a decrease of 91.07.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 45.18. This value is within the healthy range. It has increased from 36.90 (Mar 24) to 45.18, marking an increase of 8.28.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 28.79. This value is within the healthy range. It has increased from 23.63 (Mar 24) to 28.79, marking an increase of 5.16.
- For Enterprise Value (Cr.), as of Mar 25, the value is 22,744.56. It has increased from 15,271.32 (Mar 24) to 22,744.56, marking an increase of 7,473.24.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 13.62. This value exceeds the healthy maximum of 3. It has increased from 11.10 (Mar 24) to 13.62, marking an increase of 2.52.
- For EV / EBITDA (X), as of Mar 25, the value is 41.97. This value exceeds the healthy maximum of 15. It has increased from 36.62 (Mar 24) to 41.97, marking an increase of 5.35.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 13.61. This value exceeds the healthy maximum of 3. It has increased from 11.08 (Mar 24) to 13.61, marking an increase of 2.53.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 88.85 (Mar 24) to 0.00, marking a decrease of 88.85.
- For Price / BV (X), as of Mar 25, the value is 8.21. This value exceeds the healthy maximum of 3. It has decreased from 10.37 (Mar 24) to 8.21, marking a decrease of 2.16.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 13.61. This value exceeds the healthy maximum of 3. It has increased from 11.08 (Mar 24) to 13.61, marking an increase of 2.53.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Poly Medicure Ltd:
- Net Profit Margin: 19.96%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.27% (Industry Average ROCE: 13.22%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.24% (Industry Average ROE: 10.35%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 28.79
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 4.41
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 54 (Industry average Stock P/E: 23.81)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 19.96%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Equipment & Accessories | No. 232-B, 3rd Floor, New Delhi Delhi 110020 | investorcare@polymedicure.com http://www.polymedicure.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Devendra Raj Mehta | Chairman |
| Mr. Himanshu Baid | Managing Director |
| Mr. Rishi Baid | Joint Managing Director |
| Mr. Jugal Kishore Baid | Non Executive Director |
| Mrs. Mukulika Baid | Non Executive Director |
| Mr. Alessandro Balboni | Non Executive Director |
| Dr. Shailendra Raj Mehta | Ind. Non-Executive Director |
| Dr. Ambrish Mithal | Ind. Non-Executive Director |
| Dr. Sandeep Bhargava | Ind. Non-Executive Director |
| Mr. Vimal Bhandari | Ind. Non-Executive Director |
| Mr. Amit Khosla | Ind. Non-Executive Director |
| Ms. Sonal Mattoo | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Poly Medicure Ltd?
Poly Medicure Ltd's intrinsic value (as of 28 October 2025) is 1866.74 which is 2.06% lower the current market price of 1,906.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 19,316 Cr. market cap, FY2025-2026 high/low of 3,358/1,821, reserves of ₹2,715 Cr, and liabilities of 3,192 Cr.
What is the Market Cap of Poly Medicure Ltd?
The Market Cap of Poly Medicure Ltd is 19,316 Cr..
What is the current Stock Price of Poly Medicure Ltd as on 28 October 2025?
The current stock price of Poly Medicure Ltd as on 28 October 2025 is 1,906.
What is the High / Low of Poly Medicure Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Poly Medicure Ltd stocks is 3,358/1,821.
What is the Stock P/E of Poly Medicure Ltd?
The Stock P/E of Poly Medicure Ltd is 54.0.
What is the Book Value of Poly Medicure Ltd?
The Book Value of Poly Medicure Ltd is 273.
What is the Dividend Yield of Poly Medicure Ltd?
The Dividend Yield of Poly Medicure Ltd is 0.18 %.
What is the ROCE of Poly Medicure Ltd?
The ROCE of Poly Medicure Ltd is 20.1 %.
What is the ROE of Poly Medicure Ltd?
The ROE of Poly Medicure Ltd is 15.8 %.
What is the Face Value of Poly Medicure Ltd?
The Face Value of Poly Medicure Ltd is 5.00.